Bone turnover in postmenopausal women during denosumab treatment: Biomarker analysis in naive and discontinuing patients

Objectives: Osteoporosis is characterized by an imbalance in bone turnover, with increased resorption over formation. Antiresorptive treatment, such as denosumab (Dmab), aims to restore this balance, making monitoring of bone turnover markers useful. Key bone resorption parameters are serum C-terminal telopeptide of type I collagen (CTX) and urinary deoxypyridinoline/creatinine (DPD). Methods: = 21,802) was used to examine the correlation between CTX and DPD. Results: = 0.431). Conclusions: Our data suggest that urinary DPD may provide additional biochemical information in certain clinical contexts, particularly after denosumab discontinuation. Thus, simultaneous assessment of CTX and DPD may enhance diagnostic accuracy and may guide individualized osteoporosis management; however, prospective validation is needed.